3-benzyl-4-oxo-2-sulfanylidene-1H-quinazoline-7-carboxylic Acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-benzyl-4-oxo-2-sulfanylidene-1H-quinazoline-7-carboxylic Acid
• 化学式: C₁₆H₁₂N₂O₃S
• mdl: MFCD02111446
• 分子量: 312.3
• InChiKey: HTASGNOHACSDQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.062
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• KDAC VARIANTS AND USES THEREOF
  申请人：Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.

  公开号：US20200240995A1

  公开（公告）日：2020-07-30

  The invention provides a method of selecting a mutant polypeptide having lysine demodification, in particular lysine deacylation, activity, wherein the method comprises the following steps (a) incubating a mutant polypeptide having an amino acid sequence with at least 80% sequence identity to SEQ ID NO: 1 with a peptide or polypeptide comprising an inactivated essential lysine residue; and (b) determining the activity of the mutant polypeptide to activate the peptide or polypeptide comprising the inactivated essential lysine residue, wherein the mutant polypeptide and the peptide or polypeptide comprising an inactivated essential lysine residue are incubated in a biological cell. The invention furthermore relates to an acylated luciferase, particularly Firefly luciferase, and uses thereof. The present invention furthermore relates to a mutant polypeptide comprising an amino acid sequence having at least 98% sequence homology with SEQ ID NOs: 2, 3, 4, 5 or 6 and having lysine demodification, in particular lysine deacylation, activity, wherein the mutant polypeptide is not identical to SEQ ID NO: 1. The invention also relates to the mutant polypeptide of the invention and a peptide or polypeptide comprising an inactivated essential lysine residue for use in treating cancer.